Edwards Lifesciences Corp (NYSE:EW) was downgraded by equities research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a report released on Monday. They presently have a $105.74 price target on the medical research company’s stock. Vetr‘s target price indicates a potential upside of 10.30% from the stock’s previous close.
A number of other analysts have also recently weighed in on EW. Jefferies Group LLC restated a “buy” rating and issued a $115.00 price target on shares of Edwards Lifesciences Corp in a research note on Friday, December 9th. Northland Securities restated an “outperform” rating and issued a $105.00 price target on shares of Edwards Lifesciences Corp in a research note on Monday, February 27th. BTIG Research restated a “buy” rating and issued a $110.00 price target on shares of Edwards Lifesciences Corp in a research note on Saturday, December 10th. JMP Securities restated an “equal weight” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corp in a research note on Saturday, December 10th. Finally, Canaccord Genuity restated a “buy” rating and issued a $140.00 price target on shares of Edwards Lifesciences Corp in a research note on Friday, December 9th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $118.16.
Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 0.29% during trading on Monday, hitting $95.87. The stock had a trading volume of 1,870,673 shares. Edwards Lifesciences Corp has a 12-month low of $81.12 and a 12-month high of $121.75. The stock has a market cap of $20.37 billion, a price-to-earnings ratio of 36.73 and a beta of 0.53. The stock’s 50-day moving average is $92.47 and its 200-day moving average is $98.37.
Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Wednesday, February 1st. The medical research company reported $0.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.72 by $0.03. Edwards Lifesciences Corp had a return on equity of 25.00% and a net margin of 19.22%. The company had revenue of $767.70 million for the quarter, compared to analysts’ expectations of $760.85 million. During the same period last year, the firm earned $0.64 earnings per share. Edwards Lifesciences Corp’s quarterly revenue was up 14.4% on a year-over-year basis. On average, equities research analysts expect that Edwards Lifesciences Corp will post $3.41 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Mideast Time and is the sole property of of Mideast Time. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.mideasttime.com/vetr-inc-downgrades-edwards-lifesciences-corp-ew-to-buy/1589668.html.
In other Edwards Lifesciences Corp news, Director Kieran Gallahue acquired 3,000 shares of the stock in a transaction on Friday, February 3rd. The shares were bought at an average price of $90.10 per share, with a total value of $270,300.00. Following the acquisition, the director now owns 2,524 shares of the company’s stock, valued at $227,412.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 13,720 shares of Edwards Lifesciences Corp stock in a transaction that occurred on Thursday, January 12th. The shares were sold at an average price of $97.47, for a total value of $1,337,288.40. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 53,000 shares of company stock worth $276,800 and sold 125,640 shares worth $11,739,687. 2.37% of the stock is currently owned by insiders.
A number of large investors have recently made changes to their positions in EW. Norges Bank acquired a new stake in shares of Edwards Lifesciences Corp during the fourth quarter worth $217,484,000. Russell Investments Group Ltd. acquired a new stake in shares of Edwards Lifesciences Corp during the fourth quarter worth $69,018,000. Marshall Wace LLP raised its stake in shares of Edwards Lifesciences Corp by 5,253.3% in the fourth quarter. Marshall Wace LLP now owns 713,323 shares of the medical research company’s stock worth $66,839,000 after buying an additional 699,998 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in shares of Edwards Lifesciences Corp during the fourth quarter worth $58,091,000. Finally, 1832 Asset Management L.P. acquired a new stake in shares of Edwards Lifesciences Corp during the third quarter worth $67,325,000. 83.99% of the stock is currently owned by institutional investors.
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.